The expansion in Agawam, Massachusetts, includes constructing and equipping new pharmaceutical testing laboratory facilities, a series of segregated virology testing laboratories, and new aseptic fill/finish manufacturing facilities, along with the hiring of additional staff.
Microtest's pharmaceutical and virology test services can support full in-process and product release testing as well as product stability testing, raw material qualification and assay development/validation.
"Customers of our testing services and pharmaceutical contract manufacturing operations are both benefiting from the investments we're making in new facilities, laboratories, technology, and skilled personnel," said Steve Richter, Microtest's president and scientific director.
"Moreover, since we ourselves manufacture pharmaceutical product, as a growing provider of fill/finish operations, we have all the systems and procedures in place to fully support all the requirements of the US Food and Drug Administration (FDA), European Medicines Agency (EMEA) and any drug-regulating body in the world."
The company has also widened the range of medical device services and analytical services it offers for medical device designers and manufacturers.
"We have expanded our facilities, resources, and technology in the delivery of medical device sterilization validations, package validations, microbiology and clean room services, as well as dedicated a new, state-of-the-art laboratory to our full range of analytical services," Richter said.
"When combined, we offer unique single-source solutions that minimize schedule disruptions and accelerate time to revenue."
Microtest claims its problem-solving approach, customer service focus, technical guidance and expertise help customers reduce costs and risk, support rapid regulatory approvals, and enjoy reliable, fast, turn-arounds.